Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial
Authors' conclusion
Despite efforts to facilitate medication uptake in the feasibility phase of the PRECIDENTD pragmatic trial, barriers to initiation and ongoing use challenge the use of combination SGLT2i and GLP-1RA in T2D.
Study context
- Population
- Insured adults with T2D and ASCVD or high ASCVD risk
- Participants
- 173 insured participants
- Comparison
- Dual therapy vs monotherapy
- Dual therapyn = 60
- Monotherapyn = 113reference
- Primary endpoint
- Medication fill and discontinuation rates of assigned medication(s)
Methodological detailspragmatic, feasibility phase, 1:1:1
- Pragmatic
- Feasibility phase
- 1:1:1
Primary result
As reported in the abstract
Fill rate · 4 months after randomization
P < 0.001
Further findings
Fill rate overall · 10-month median follow-up
P = 0.004
Discontinuation of a study medication (among those who filled) · mostly due to side effects
P = 0.002
Patient-Reported Outcomes Measurement Information System (PROMIS) and mKCCQ-12 scores
- No change
Original publication
Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial. Am Heart J. Published 26 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →